Template:Targeted cancer therapeutic agents

From WikiMD's Wellness Encyclopedia

Targeted cancer therapy / antineoplastic agents (L01)

CI monoclonal antibodies ("-mab")

Receptor tyrosine kinase	* ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Pertuzumab, Trastuzumab (+hyaluronidase) Trastuzumab emtansine Trastuzumab deruxtecan)
Others for solid tumors	* EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab)
Leukemia/lymphoma	* lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab ozogamicin)
Other	* Amivantamab Atezolizumab Avelumab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Inotuzumab ozogamicin Ipilimumab Isatuximab Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Necitumumab Nivolumab Olaratumab Pembrolizumab Polatuzumab vedotin Ramucirumab Retifanlimab Tafasitamab

Tyrosine kinase inhibitors ("-nib")

Receptor tyrosine kinase

* ErbB: HER1/EGFR (Afatinib

HER1/EGFR and HER2/neu

RTK class III: C-kit and PDGFR (Avapritinib
Axitinib
Masitinib
Pazopanib
Ripretinib
Sorafenib
Sunitinib
Toceranib)
FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK))

VEGFR
- Axitinib
- Cediranib
- Fruquintinib
- Lenvatinib
- Nintedanib
- Pazopanib
- Regorafenib
- Semaxanib
- Sorafenib
- Sunitinib
- Tivozanib
- Toceranib
- Vandetanib

ALK

RET inhibitors: Entrectinib (ALK, ROS1, NTRK), Futibatinib (FGFR2), Infigratinib, Larotrectinib (NTRK), Pemigatinib (FGFR), Pralsetinib, Repotrectinib (ROS1, TRK, ALK), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).

c-MET inhibitors: Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)

* bcr-abl

- Asciminib
- Bosutinib
- Dasatinib
- Imatinib
- Nilotinib
- Ponatinib
- Radotinib

Src (Bosutinib
Dasatinib)

Janus kinase

MAP2K

EML4-ALK

Bruton's

Other

* fusion protein against VEGF (Aflibercept)

proapoptotic peptide against ANXA2 and prohibitin (Adipotide)
exotoxin against IL-2 (Denileukin diftitox)
mTOR inhibitors
- Everolimus
- Ridaforolimus
- Temsirolimus
hedgehog inhibitors
- Glasdegib
- Sonidegib
- Vismodegib
CDK inhibitors
- Abemaciclib
- Dalpiciclib
- Palbociclib
- Ribociclib
- Trilaciclib
KRAS inhibitors
- Adagrasib
- Sotorasib
Cabozantinib
Capmatinib
Entrectinib
Erdafitinib
Gilteritinib
Larotrectinib
Lenvatinib
Masitinib
Midostaurin
Nintedanib
Pazopanib
Pemigatinib
Pexidartinib
Quizartinib
Regorafenib
Ripretinib
Sorafenib
Sunitinib
Tebentafusp
Tepotinib
Vandetanib
Venetoclax

Retrieved from "https://wikimd.com/index.php?title=Template:Targeted_cancer_therapeutic_agents&oldid=5674389"

Noindexed pages